Pharmacologic reprogramming of virus-tumor crosstalk enhances measles virus antitumor activity in BRAF mutant colorectal cancer models.

doi:10.1186/s13046-026-03749-9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacologic reprogramming of virus-tumor crosstalk enhances measles virus antitumor activity in BRAF mutant colorectal cancer models.

Journal of experimental & clinical cancer research : CR - 6 Jun 2026

Chavez Valery, Montero Melissa, Tran Ngoc Huong Giang, Mendes Carolina Merchan, Ban Yuguang, Khurana Rimpi, Ceccarelli Michelle, Merchan Jaime R

Abstract excerpt

BACKGROUND: Oncolytic viruses are promising cancer biotherapies but often show limited durability as single agents due to tumor-intrinsic resistance mechanisms. Because therapeutic efficacy is shaped by dynamic virus-tumor-stromal interactions, pharmacologic strategies that reprogram this interface may enhance virotherapy responses. Here, we investigate whether targeting tumor stress and survival pathways with...

Read the complete abstract on PubMed

Topics

Humans
Animals
Measles virus
Colorectal Neoplasms
Oncolytic Virotherapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mice

Xenograft Model Antitumor Assays

Proto-Oncogene Proteins B-raf

Mutation

Epoxy Compounds

Diterpenes

Cell Line, Tumor

Oncolytic Viruses

Phenanthrenes

Source

Open in PubMed Open full text

Identifiers

PMID: 42251341
DOI: 10.1186/s13046-026-03749-9
PMCID: PMC13536603

Genes

BRAF
CD46

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic reprogramming of virus-tumor crosstalk enhances measles virus antitumor activity in BRAF mutant colorectal cancer models.PMID 42251341Read ↗

Reovirus sensitizes microsatellite stable colorectal cancer to anti-PD-1 treatment via cross-talk in innate and adaptive immune systemsSemantic proximity Read ↗

The oncolytic virus ΔPK has multimodal anti-tumor activity.Semantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

Extracellular vesicle-mediated gene therapy targets BRAFV600E-mutant colorectal cancer by inhibiting the MEK1/2-ERK1/2 pathwaySemantic proximity Read ↗

Oncolytic virotherapy: the questions and the promiseSemantic proximity Read ↗

A system-wide approach to monitor responses to synergistic BRAF and EGFR inhibition in colorectal cancer cellsSemantic proximity Read ↗

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus ImmunotherapySemantic proximity Read ↗

A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.Semantic proximity Read ↗

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial.Semantic proximity Read ↗

Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxiaSemantic proximity Read ↗

From Scourge to Cure: Tumour-Selective Viral Pathogenesis as a New Strategy against CancerSemantic proximity Read ↗

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.